Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 4, 2021

Eurofins introduces new assay for Indian SARS-CoV-2 variant

GSD NovaType III SARS-CoV-2 RT-PCR assay can detect mutations such as E484Q, E484K and L452R in a single reaction.

Eurofins Technologies has introduced its GSD NovaType III SARS-CoV-2 RT-PCR assay for quick identification of the SARS-CoV-2 variant B.1.617, which was first detected in India.

The assay can also identify other SARS-CoV-2 variants of concern, which include B.1.427/B.1.429 (California, US), B.1.351 (South Africa) and P.1 (Brazil).

The test can detect related mutations E484Q, E484K and L452R in a single reaction and simultaneously distinguish from the S gene E484 wildtype variant.

These mutations are linked to reports of possibly lowered efficacy of some vaccines and a hike in the Covid-19 virus transmissibility, Eurofins noted.

The latest assay is an addition to the GSD NovaType product line, which includes single and multiplex assays to diagnose and identify emerging variants of concern and of interest on positive samples.

These assays could help fight Covid-19 via quick detection of new variants that could impact global inoculation campaigns as well as deployment of isolation, testing and vaccination processes in affected regions, the company added.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

By 9 June, GSD NovaType III SARS-CoV-2 will be available for research use while a CE marked version is anticipated in the coming weeks.

In a separate development, the Indian Council of Medical Research (ICMR) has granted approval to US-based Abbott Rapid Diagnostics’ at-home rapid antigen test kit.

The PanBio Covid19 Antigen Test Device is a self-use kit that secured provisional approval till 5 July. The kit’s price is yet to be announced by the company.

Last month, the ICMR granted approval to Mylab Discovery Solutions’ CoviSelf test kit. The first home-based test approved in India, each kit costs $3.42 (Rs250).

The ICMR has given an advisory on the usage of self-test kits. The rapid antigen test is recommended only for use in symptomatic people and immediate contacts of lab-confirmed positive Covid-19 cases.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU